Clinical Trials Sponsored by Innovus Pharmaceuticals, Inc.

Total 5021 results

Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects

End Stage Renal Disease
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

Pain | Advanced Cancer

United States, United Kingdom, Bulgaria, Belgium, Poland, Hungary, Romania, Czechia, Puerto Rico, Lithuania, Germany, Latvia
Tracon Pharmaceuticals Inc.
Janssen Pharmaceutica N.V., Belgium

Completed

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Metastatic Castrate-resistant Prostate Cancer | Adenocarcinoma, Prostate

United States
Auspex Pharmaceuticals, Inc.

Completed

Alternatives for Reducing Chorea in Huntington Disease (ARC-HD)

Chorea Associated With Huntington Disease

United States, Australia, Canada
Auspex Pharmaceuticals, Inc.

Completed

Reducing Involuntary Movements in Participants With Tardive Dyskinesia (RIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia
Auspex Pharmaceuticals, Inc.

Completed

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)

TOURETTE SYNDROME

United States
Auspex Pharmaceuticals, Inc.

Completed

Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia
Auspex Pharmaceuticals, Inc.

Completed

Aim to Reduce Movements in Tardive Dyskinesia (ARM-TD)

Tardive Dyskinesia

United States, Poland, Czechia, Slovakia
Navitor Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.

Completed

Mass Balance Study of NV-5138 in Healthy Male Subjects.

Healthy Volunteers

United Kingdom
InnoVec Biotherapeutics Inc.
Peking Union Medical College Hospital

Recruiting

Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis

Eye Diseases | Retinal Degeneration | Retinal Disease | Retinoschisis

China
Navitor Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.

Recruiting

Open-Label of SPN-820 in Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Navitor Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.

Recruiting

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

Treatment Resistant Depression

United States
Tasly Pharmaceuticals, Inc.
Tasly Pharmaceutical Group Co., Ltd

No longer available

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

Covid19

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates; Triangle Biostatistics

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Spain, Canada, Australia, United Kingdom, Germany, Netherlands, Belgium, Austria, France
Mylan Pharmaceuticals Inc
Momenta Pharmaceuticals, Inc.

Completed

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME) (DME)

Diabetic Macular Edema

Japan, United States, Czechia, Germany, Hungary, India, Latvia, Poland, Russian Federation
Massachusetts General Hospital
Alkermes, Inc.; Otsuka America Pharmaceutical; Eisai Inc.; Janssen Pharmaceuticals and other collaborators

Recruiting

National Pregnancy Registry for Atypical Antipsychotics

Depression | Schizophrenia | Schizoaffective Disorder | Bipolar Disorder | Use of Atypical Antipsychotics During Pregnancy

United States
Mylan Pharmaceuticals Inc
Momenta Pharmaceuticals, Inc.

Completed

Extension Study of MYL-1701P-3001 for Safety and Efficacy

Diabetic Macular Edema

India
Annovis Bio Inc.
Alzheimer's Disease Cooperative Study (ADCS)

Completed

Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease (DISCOVER)

Alzheimer's Disease

United States
NovaBay Pharmaceuticals, Inc.
Novum Pharmaceutical Research Services; International Dermatology Research,...

Completed

Safety and Efficacy of Topical NVC-422 Gel in Impetigo

Impetigo

Dominican Republic
Nucorion Pharmaceuticals, Inc.
Medpace, Inc.; Ligand Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects

Hepatitis B

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Belgium
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Austria
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

Multiple Myeloma

Belgium, France, Germany
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Urinary Tract Infections | Pyelonephritis
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Non-Small Cell Lung Cancer

Belgium
Corbus Pharmaceuticals Inc.
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Solid Tumor, Adult

United States, Spain, Turkey, United Kingdom
MingSight Pharmaceuticals, Inc
Shenzhen MingSight Relin Pharmaceutical Co., Ltd

Recruiting

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)

China
ChemGenex Pharmaceuticals

Terminated

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

Myeloid Leukemia, Chronic, Chronic-Phase | Myeloid Leukemia, Chronic | Myeloid Leukemia, Chronic, Accelerated-Phase | Blast Phase

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Follicular Lymphoma

Italy, Israel, Germany, France, Greece, Spain, Switzerland
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

France, United States, Spain, Korea, Republic of, Australia, Israel, India, Thailand, China, Czech Republic, Belgium, New Zealand, Russian Federation, Finland, South Africa, United Kingdom, Italy, Brazil, Hungary, Puerto Rico, A... and more
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

Amyloidosis

United States
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Bacterial Infections and Mycoses | Cholecystitis | Appendicitis | Peritonitis | Pancreatitis
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Bacterial Infections and Mycoses | Cholecystitis | Appendicitis | Peritonitis | Pancreatitis
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Hospital-Acquired Pneumonia

Pneumonia
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Urinary Tract Infections | Pyelonephritis
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

Tumors | Non-Hodgkins's Lymphoma

United States
ChemGenex Pharmaceuticals

Completed

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Hematologic Tumors

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

Multiple Myeloma | Non-Hodgkin's Lymphoma

Israel, Italy, Poland, South Africa, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Ventilator-Associated Pneumonia

Pneumonia | Ventilators, Mechanical
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

NSCLC

United States
Ligand Pharmaceuticals
CyDex Pharmaceuticals, Inc.

Withdrawn

Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

Contrast-induced Nephropathy
Paratek Pharmaceuticals Inc
Novartis Pharmaceuticals

Terminated

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) (CSSI)

Skin Diseases, Infectious

United States
Nucorion Pharmaceuticals, Inc.
Ligand Pharmaceuticals

Completed

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

Chronic Hepatitis B

United States
Semafore Pharmaceuticals
SignalRX Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)

Cancer | Advanced or Metastatic Solid Tumors | Solid Cancers

United States
Conatus Pharmaceuticals Inc.
Idun Pharmaceuticals

Completed

A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

Hepatitis C, Chronic

United States
Conatus Pharmaceuticals Inc.
Idun Pharmaceuticals

Completed

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

Liver Transplantation | Hepatitis | Carcinoma, Hepatocellular | Cholestasis

United States, Germany
Alexion Pharmaceuticals, Inc.

Not yet recruiting

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

Paroxysmal Nocturnal Hemoglobinuria | PNH | Extravascular Hemolysis
Ionis Pharmaceuticals, Inc.

Not yet recruiting

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Clinical Trials Sponsored by Innovus Pharmaceuticals, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations